Published Date: 11/06/2023
Expiration Date: 10/10/2026
The risks for hepatitis B and D lurk in the background for anyone with or at-risk for HIV. It is particularly important to keep this in mind when patients initiate or change medications for HIV and PrEP. Of course, we have had safe and effective vaccinations to prevent hepatitis B for many years, but for patients who have a history of hepatitis B, and are therefore at risk for hepatitis D, additional monitoring is necessary, and extra caution is advised when changing HIV treatment or prevention strategies, to guard against hepatic flare or rebound. In this important program, Dr. Debika Bhattacharya. the Chair of the Hepatitis Transformative Science Group (TSG) within the AIDS Clinical Trials Group (ACTG), will address these issues and provide updates in the management of hepatitis B and D.
Dr. Bhattacharya is a Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles with a joint appointment at the Greater Los Angeles VA Healthcare System. Her research has focused on clinical outcomes in persons living with HIV and viral hepatitis, and, more recently, clinical therapeutics for HBV, which have been funded through NIH support. She is the Chair of the Hepatitis Transformative Science Group (TSG) within the AIDS Clinical Trials Group (ACTG), where she leads the scientific agenda for novel HBV therapeutics for the world’s largest HIV clinical trials organization. She is the IDSA co-chair of the AASLD/IDSA Hepatitis C Treatment Guidance Panel. Her roles at the GLAVAHCS include being co-director of the Viral Hepatitis Program of the Greater Los Angeles Veterans Affairs Healthcare System (GLAVAHS) and co-Director of the NODES program. She is also a member of the Writing Panel for the NIH-CDC-HIVMA/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.